Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high...
Saved in:
| Published in | Circulation. Cardiovascular interventions Vol. 12; no. 4; p. e007811 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
American Heart Association, Inc
01.04.2019
|
| Online Access | Get full text |
| ISSN | 1941-7640 1941-7632 |
| DOI | 10.1161/CIRCINTERVENTIONS.119.007811 |
Cover
| Abstract | Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention. The Food and Drug Administration has issued a black box warning advising practitioners to consider alternative treatment in CYP2C19 poor metabolizers who might receive clopidogrel and to identify such patients by genotyping. However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by clinical guidelines because of lack of prospective evidence. To address this critical gap, TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) is a large, pragmatic, randomized trial comparing point-of-care genotype-guided antiplatelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative antiplatelet therapy is beneficial. |
|---|---|
| AbstractList | Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention. The Food and Drug Administration has issued a black box warning advising practitioners to consider alternative treatment in CYP2C19 poor metabolizers who might receive clopidogrel and to identify such patients by genotyping. However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by clinical guidelines because of lack of prospective evidence. To address this critical gap, TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) is a large, pragmatic, randomized trial comparing point-of-care genotype-guided antiplatelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative antiplatelet therapy is beneficial. Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention. The Food and Drug Administration has issued a black box warning advising practitioners to consider alternative treatment in CYP2C19 poor metabolizers who might receive clopidogrel and to identify such patients by genotyping. However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by clinical guidelines because of lack of prospective evidence. To address this critical gap, TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) is a large, pragmatic, randomized trial comparing point-of-care genotype-guided antiplatelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative antiplatelet therapy is beneficial. Common genetic variation in CYP2C19 (*2 and *3 alleles) leads to a loss of functional protein and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel-active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after PCI. The Food and Drug Administration has issued a black box warning advising practitioners to “consider alternative treatment in CYP2C19 poor metabolizers” who might receive clopidogrel and to identify such patients by genotyping. However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing PCI is not recommended by clinical guidelines due to lack of prospective evidence. To address this critical gap, TAILOR-PCI is a large, pragmatic, randomized trial comparing point-of-care genotype-guided anti-platelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative anti-platelet therapy is beneficial. |
| Author | So, Derek Y.F. Iturriaga, Erin Geller, Nancy Rosenberg, Yves Weinshilboum, Richard M. Wang, Liewei Rihal, Charanjit S. Lerman, Amir Lennon, Ryan J. Mathew, Verghese Goodman, Shaun G. Fu, Yi-Ping Pereira, Naveen L. Hasan, Ahmed Farkouh, Michael E. Bailey, Kent Baudhuin, Linnea M. |
| AuthorAffiliation | Department of Cardiovascular Medicine (N.L.P., C.S.R., A.L.), Mayo Clinic, Rochester, MN. Department of Health Sciences Research (R.J.L., K.B.), Mayo Clinic, Rochester, MN. Department of Molecular Pharmacology and Experimental Therapeutics (N.L.P., R.M.W., L.W.), Mayo Clinic, Rochester, MN. Department of Laboratory Medicine and Pathology (L.M.B.), Mayo Clinic, Rochester, MN. University of Ottawa Heart Institute, Ontario, Canada (D.Y.F.S.). National Heart, Lung, and Blood Institute, Bethesda, MD (Y.R., A.H., E.I., Y.-P.F., N.G.). Division of Cardiology, Loyola University Health System, Loyola University Chicago Stritch School of Medicine, Maywood, IL (V.M.). St. Michael’s Hospital, University of Toronto, Ontario, Canada (S.G.G.). Peter Munk Cardiac Centre, Heart and Stroke Richard Lewar Centre, University of Toronto, Canada (M.E.F.) |
| AuthorAffiliation_xml | – name: Department of Cardiovascular Medicine (N.L.P., C.S.R., A.L.), Mayo Clinic, Rochester, MN. Department of Health Sciences Research (R.J.L., K.B.), Mayo Clinic, Rochester, MN. Department of Molecular Pharmacology and Experimental Therapeutics (N.L.P., R.M.W., L.W.), Mayo Clinic, Rochester, MN. Department of Laboratory Medicine and Pathology (L.M.B.), Mayo Clinic, Rochester, MN. University of Ottawa Heart Institute, Ontario, Canada (D.Y.F.S.). National Heart, Lung, and Blood Institute, Bethesda, MD (Y.R., A.H., E.I., Y.-P.F., N.G.). Division of Cardiology, Loyola University Health System, Loyola University Chicago Stritch School of Medicine, Maywood, IL (V.M.). St. Michael’s Hospital, University of Toronto, Ontario, Canada (S.G.G.). Peter Munk Cardiac Centre, Heart and Stroke Richard Lewar Centre, University of Toronto, Canada (M.E.F.) – name: 8 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota – name: 2 University of Ottawa Heart Institute, Ottawa, Ontario, Canada – name: 7 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota – name: 4 Department of Health Sciences Research, Mayo Clinic, Rochester – name: 6 St. Michael’s Hospital, Toronto, Ontario, Canada – name: 3 National Heart, Lung, and Blood Institute, Bethesda, Maryland – name: 5 Department of Medicine, Loyola University, Mayowood, Illinois – name: 1 Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Minnesota |
| Author_xml | – sequence: 1 givenname: Naveen surname: Pereira middlename: L. fullname: Pereira, Naveen L. organization: Department of Cardiovascular Medicine (N.L.P., C.S.R., A.L.), Mayo Clinic, Rochester, MN. Department of Health Sciences Research (R.J.L., K.B.), Mayo Clinic, Rochester, MN. Department of Molecular Pharmacology and Experimental Therapeutics (N.L.P., R.M.W., L.W.), Mayo Clinic, Rochester, MN. Department of Laboratory Medicine and Pathology (L.M.B.), Mayo Clinic, Rochester, MN. University of Ottawa Heart Institute, Ontario, Canada (D.Y.F.S.). National Heart, Lung, and Blood Institute, Bethesda, MD (Y.R., A.H., E.I., Y.-P.F., N.G.). Division of Cardiology, Loyola University Health System, Loyola University Chicago Stritch School of Medicine, Maywood, IL (V.M.). St. Michael’s Hospital, University of Toronto, Ontario, Canada (S.G.G.). Peter Munk Cardiac Centre, Heart and Stroke Richard Lewar Centre, University of Toronto, Canada (M.E.F.) – sequence: 2 givenname: Charanjit surname: Rihal middlename: S. fullname: Rihal, Charanjit S. – sequence: 3 givenname: Derek surname: So middlename: Y.F. fullname: So, Derek Y.F. – sequence: 4 givenname: Yves surname: Rosenberg fullname: Rosenberg, Yves – sequence: 5 givenname: Ryan surname: Lennon middlename: J. fullname: Lennon, Ryan J. – sequence: 6 givenname: Verghese surname: Mathew fullname: Mathew, Verghese – sequence: 7 givenname: Shaun surname: Goodman middlename: G. fullname: Goodman, Shaun G. – sequence: 8 givenname: Richard surname: Weinshilboum middlename: M. fullname: Weinshilboum, Richard M. – sequence: 9 givenname: Liewei surname: Wang fullname: Wang, Liewei – sequence: 10 givenname: Linnea surname: Baudhuin middlename: M. fullname: Baudhuin, Linnea M. – sequence: 11 givenname: Amir surname: Lerman fullname: Lerman, Amir – sequence: 12 givenname: Ahmed surname: Hasan fullname: Hasan, Ahmed – sequence: 13 givenname: Erin surname: Iturriaga fullname: Iturriaga, Erin – sequence: 14 givenname: Yi-Ping surname: Fu fullname: Fu, Yi-Ping – sequence: 15 givenname: Nancy surname: Geller fullname: Geller, Nancy – sequence: 16 givenname: Kent surname: Bailey fullname: Bailey, Kent – sequence: 17 givenname: Michael surname: Farkouh middlename: E. fullname: Farkouh, Michael E. |
| BookMark | eNqNkFtrGzEQhUVJaW79D_vQV6WjlfaiUgru4qYLxg6O21chaWe9atcro13H5N9HwSXQ9iUPYsSZOd8w55KcDX5AQj4wuGEsZx-rel3Vy818_XO-3NSr5X2U5Q1AUTL2hlwwKRgtcp6evfwFnJPLcfwFEOU8fUfOOUhZcplfkGXV-71r_DZgn9x1Ouy09VsccHJ2_JTcT3pC6ls6dUhnYUrW-ODwmOihSaKUbGb1YrWmd1UdRw_N4zV52-p-xPd_6hX58W2-qb7Txeq2rmYLanleAG1tajNkvG2LzPDCSNNq24i8lEZaTEsDItPC6FIUBkUroYzniSazXBubSc2vyJcTd38wO2wsDlPQvdoHt9PhUXnt1N-dwXVq6x9UnpUshSwCPp8ANvhxDNi-eBmo55zVfzlHWapTztH-9R-7dTEq55-3uf61EHGCHH0_YRh_94cjBtWh7qdOAeO8EDKjKTAJAgBofAz4ExJFmik |
| CitedBy_id | crossref_primary_10_1159_000534466 crossref_primary_10_1161_ATVBAHA_120_314446 crossref_primary_10_3390_app11199078 crossref_primary_10_1016_j_jcin_2021_01_024 crossref_primary_10_1016_j_heliyon_2023_e22214 crossref_primary_10_3390_jpm12081267 crossref_primary_10_1177_17474930221111898 crossref_primary_10_1016_j_jccase_2023_08_011 crossref_primary_10_1161_CIRCGEN_120_002964 crossref_primary_10_18632_aging_202799 crossref_primary_10_1177_10760296251327594 crossref_primary_10_1161_JAHA_121_024156 crossref_primary_10_3390_cimb45040228 crossref_primary_10_1002_bmc_5714 crossref_primary_10_3389_fcvm_2022_991646 crossref_primary_10_1016_j_avsg_2024_09_031 crossref_primary_10_1093_eurheartj_ehab642 crossref_primary_10_3390_jcm12031149 crossref_primary_10_1186_s12872_021_02201_4 crossref_primary_10_3390_ijerph19020647 crossref_primary_10_3389_fcvm_2022_925518 crossref_primary_10_1055_s_0041_1735193 crossref_primary_10_1016_j_microc_2024_110948 crossref_primary_10_37489_2588_0527_2022_1_53_62 crossref_primary_10_1016_j_jacc_2021_04_001 crossref_primary_10_1146_annurev_pharmtox_051921_092701 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107684 crossref_primary_10_62347_EWUH3396 crossref_primary_10_1002_jcla_23970 crossref_primary_10_2147_DDDT_S297918 crossref_primary_10_1016_j_jcin_2024_08_027 crossref_primary_10_3390_jpm11090851 crossref_primary_10_3390_mi14030541 crossref_primary_10_1002_cpt_3028 crossref_primary_10_1002_cpt_2215 crossref_primary_10_2217_pgs_2020_0198 crossref_primary_10_2174_1875692118666210810092755 crossref_primary_10_1016_j_jcin_2023_01_363 crossref_primary_10_1007_s10557_022_07392_2 crossref_primary_10_1016_j_heliyon_2023_e18573 crossref_primary_10_1080_14740338_2021_1936498 crossref_primary_10_1007_s10238_025_01602_5 crossref_primary_10_31083_j_rcm2311360 crossref_primary_10_3390_antiox11030507 crossref_primary_10_2147_CPAA_S242675 crossref_primary_10_1093_ehjopen_oead134 crossref_primary_10_18705_2782_3806_2024_4_4_295_312 crossref_primary_10_29039_2712_8164_2023_1_17_26 crossref_primary_10_3390_genes14030578 crossref_primary_10_1136_jnis_2024_021845 crossref_primary_10_2147_PGPM_S231475 crossref_primary_10_4103_cmi_cmi_19_22 crossref_primary_10_1002_cpt_3552 crossref_primary_10_1016_j_jpba_2021_113901 crossref_primary_10_1161_CIRCINTERVENTIONS_121_011536 crossref_primary_10_15829_1728_8800_2021_2773 crossref_primary_10_1159_000517811 crossref_primary_10_1016_j_ejps_2024_106987 crossref_primary_10_1155_2021_4487393 crossref_primary_10_1007_s40291_021_00549_z crossref_primary_10_1371_journal_pone_0307995 crossref_primary_10_1136_heartjnl_2021_319321 crossref_primary_10_1007_s44197_023_00113_4 crossref_primary_10_1038_s41576_022_00572_8 crossref_primary_10_1016_j_heliyon_2024_e28566 crossref_primary_10_4103_jicc_jicc_14_24 crossref_primary_10_3389_fphar_2024_1326776 crossref_primary_10_7759_cureus_42169 crossref_primary_10_1186_s40360_024_00750_w crossref_primary_10_1001_jamacardio_2019_4175 crossref_primary_10_54097_ijbls_v2i1_5222 crossref_primary_10_1002_cpt_2039 crossref_primary_10_3389_fcvm_2022_1016126 crossref_primary_10_3390_jpm12122021 crossref_primary_10_1007_s10557_021_07149_3 crossref_primary_10_1002_cpt_2957 crossref_primary_10_1186_s40246_023_00495_3 crossref_primary_10_2217_pgs_2022_0106 crossref_primary_10_1007_s10557_020_06988_w crossref_primary_10_1007_s00228_020_03050_4 crossref_primary_10_1111_cts_13800 crossref_primary_10_37489_2588_0527_2023_1_46_55 crossref_primary_10_1080_09537104_2022_2052036 crossref_primary_10_3390_genes15050607 crossref_primary_10_1016_j_wneu_2024_02_013 crossref_primary_10_3389_fvets_2023_1194242 crossref_primary_10_1186_s12883_021_02127_6 crossref_primary_10_3390_jpm11050400 crossref_primary_10_3390_jcm10112371 crossref_primary_10_1002_cpt_1911 crossref_primary_10_3390_medicines11030006 crossref_primary_10_1016_j_jcin_2023_01_356 crossref_primary_10_1016_j_xhgg_2022_100100 crossref_primary_10_3390_genes11111337 crossref_primary_10_1161_STROKEAHA_124_049140 crossref_primary_10_1016_j_jacbts_2020_02_009 crossref_primary_10_3390_cells13060504 crossref_primary_10_1161_CIRCGEN_119_002640 crossref_primary_10_1097_FPC_0000000000000564 crossref_primary_10_1111_bph_17355 crossref_primary_10_20514_2226_6704_2021_11_5_380_388 crossref_primary_10_1016_j_jstrokecerebrovasdis_2022_106798 crossref_primary_10_1007_s11239_020_02075_x crossref_primary_10_1038_s41598_024_52540_3 crossref_primary_10_1097_MD_0000000000034974 crossref_primary_10_1002_ccd_28352 crossref_primary_10_1016_j_cjco_2022_07_013 crossref_primary_10_2174_1871530322666220523142229 crossref_primary_10_1007_s12170_022_00713_y crossref_primary_10_2174_1574884716666210525153454 crossref_primary_10_1016_j_ahj_2020_10_069 crossref_primary_10_1161_JAHA_124_035424 crossref_primary_10_1007_s00228_021_03176_z crossref_primary_10_1007_s00210_024_03142_3 crossref_primary_10_3389_fphar_2022_931405 crossref_primary_10_1186_s40246_022_00417_9 crossref_primary_10_1093_ehjcvp_pvae036 crossref_primary_10_2217_pgs_2022_0057 crossref_primary_10_1002_cpt_2383 crossref_primary_10_1080_17425255_2020_1804857 crossref_primary_10_1097_01_JAA_0000902916_16504_e0 crossref_primary_10_1007_s10557_021_07295_8 crossref_primary_10_3390_brainsci12081077 crossref_primary_10_1007_s11910_023_01266_2 crossref_primary_10_1097_FJC_0000000000001591 crossref_primary_10_2147_PGPM_S324612 crossref_primary_10_1002_jcph_2016 crossref_primary_10_1021_acs_chemrev_1c00574 crossref_primary_10_1111_jgs_19036 crossref_primary_10_1007_s40264_024_01416_6 crossref_primary_10_1016_j_thromres_2024_02_010 crossref_primary_10_3389_fcvm_2023_1105001 crossref_primary_10_1016_j_ahj_2021_12_005 crossref_primary_10_1093_eurheartj_ehad362 crossref_primary_10_1038_s41397_022_00278_4 crossref_primary_10_1016_j_jacc_2020_01_027 crossref_primary_10_18786_2072_0505_2022_50_016 crossref_primary_10_1161_JAHA_121_024709 crossref_primary_10_1097_FPC_0000000000000462 crossref_primary_10_1007_s10557_024_07544_6 crossref_primary_10_29001_2073_8552_2022_538 crossref_primary_10_47102_annals_acadmedsg_2023233 crossref_primary_10_3389_fphar_2022_931531 crossref_primary_10_2147_NDT_S350266 crossref_primary_10_1001_jama_2020_12443 |
| Cites_doi | 10.1016/j.cjca.2014.09.011 10.1016/j.jacc.2018.02.029 10.1056/NEJMoa0808227 10.1001/jama.2011.1880 10.1161/CIRCULATIONAHA.111.031195 10.1093/eurheartj/eht296 10.1016/j.ijcard.2017.02.062 10.1016/j.amjcard.2015.02.049 10.1056/NEJMoa0706482 10.1093/eurheartj/ehx419 10.1001/jama.2011.290 10.3390/jpm8010008 10.1016/j.thromres.2011.07.028 10.1001/jama.2009.1232 10.1016/S0140-6736(12)60161-5 10.1253/circj.CJ-15-0112 10.1056/NEJMoa0809171 10.1007/s40265-013-0126-z 10.1038/nrcardio.2009.154 10.1016/j.amjcard.2008.11.048 10.1111/j.1538-7836.2011.04483.x 10.1161/CIR.0b013e3182742cf6 10.1016/j.jacc.2007.12.056 10.1016/j.jjcc.2010.10.007 10.1016/j.jacc.2010.05.013 10.1016/j.ahj.2010.06.039 10.1161/CIR.0b013e318212bb8b 10.1111/j.1538-7836.2007.02775.x 10.1253/circj.72.1165 10.1161/CIRCINTERVENTIONS.111.963025 10.1136/hrt.2011.227272 10.1161/CIR.0000000000000404 10.1161/CIRCULATIONAHA.109.885194 10.1161/CIRCULATIONAHA.109.851949 10.1056/NEJMoa1209979 10.1016/j.jcin.2017.07.022 10.1016/j.ahj.2014.03.006 10.1016/j.jacc.2011.11.068 10.1016/j.jacc.2013.07.101 10.1001/jama.2010.1543 10.1007/s10928-008-9103-7 10.1016/S0140-6736(17)32155-4 10.1161/CIR.0000000000000133 10.1016/S0021-9258(17)40694-6 10.1161/CIRCGENETICS.110.958561 10.1016/S0140-6736(10)61274-3 10.1001/jama.2010.181 10.1124/dmd.109.029132 10.1001/jama.2011.1703 10.1161/CIR.0b013e31823a5596 10.1016/j.jacc.2018.02.036 10.1161/CIRCULATIONAHA.111.075242 10.1056/NEJMoa0904327 10.1161/CIR.0b013e3181ee08ed 10.1016/j.jacc.2010.12.047 |
| ContentType | Journal Article |
| Copyright | 2019 American Heart Association, Inc. |
| Copyright_xml | – notice: 2019 American Heart Association, Inc. |
| DBID | AAYXX CITATION 5PM |
| DOI | 10.1161/CIRCINTERVENTIONS.119.007811 |
| DatabaseName | CrossRef PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1941-7632 |
| EndPage | e007811 |
| ExternalDocumentID | PMC6581205 10_1161_CIRCINTERVENTIONS_119_007811 01337495-201904000-00010 |
| GroupedDBID | --- .XZ .Z2 0R~ 18M 53G 5VS 6J9 AAAAV AAHPQ AAIQE AAJCS AARTV AASCR ABASU ABBUW ABDIG ABJNI ABPXF ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACEWG ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADBBV ADGGA ADHPY ADNKB AEBDS AEETU AFBFQ AFDTB AFEXH AFNMH AFUWQ AGINI AHQNM AHQVU AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BAWUL BQLVK C45 CS3 DIK DIWNM DUNZO E.X E3Z EBS EEVPB EJD EX3 F5P FCALG FL- GNXGY GQDEL H13 HLJTE HZ~ IKREB IN~ IPNFZ JF7 KD2 KQ8 KQB L-C O9- ODMTH ODZKP OHYEH OK1 OPUJH OUVQU OVD OVDNE OXXIT P6G RAH RIG RLZ S4S TEORI TR2 TSPGW V2I W2D W3M W8F WOW ZZMQN AAYXX ADKSD CITATION 5PM |
| ID | FETCH-LOGICAL-c3670-fc2c5e13ff75b37b9bfacd4689b9ce28b045a4ba847be4f9080784d5c3abc59a3 |
| ISSN | 1941-7640 |
| IngestDate | Tue Sep 30 16:26:36 EDT 2025 Thu Apr 24 22:56:24 EDT 2025 Wed Oct 01 00:54:33 EDT 2025 Fri May 16 03:57:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c3670-fc2c5e13ff75b37b9bfacd4689b9ce28b045a4ba847be4f9080784d5c3abc59a3 |
| PMID | 30998396 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6581205 crossref_primary_10_1161_CIRCINTERVENTIONS_119_007811 crossref_citationtrail_10_1161_CIRCINTERVENTIONS_119_007811 wolterskluwer_health_01337495-201904000-00010 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-April 2019-04-00 20190401 |
| PublicationDateYYYYMMDD | 2019-04-01 |
| PublicationDate_xml | – month: 04 year: 2019 text: 2019-April |
| PublicationDecade | 2010 |
| PublicationTitle | Circulation. Cardiovascular interventions |
| PublicationYear | 2019 |
| Publisher | American Heart Association, Inc |
| Publisher_xml | – name: American Heart Association, Inc |
| References | e_1_3_4_3_2 e_1_3_4_7_2 e_1_3_4_40_2 e_1_3_4_5_2 e_1_3_4_23_2 e_1_3_4_44_2 e_1_3_4_21_2 e_1_3_4_42_2 e_1_3_4_27_2 e_1_3_4_48_2 e_1_3_4_25_2 e_1_3_4_46_2 e_1_3_4_29_2 De Morais SM (e_1_3_4_9_2) 1994; 46 e_1_3_4_30_2 e_1_3_4_51_2 e_1_3_4_11_2 e_1_3_4_34_2 e_1_3_4_57_2 e_1_3_4_55_2 e_1_3_4_32_2 e_1_3_4_59_2 e_1_3_4_53_2 e_1_3_4_15_2 e_1_3_4_38_2 e_1_3_4_13_2 e_1_3_4_36_2 e_1_3_4_19_2 e_1_3_4_17_2 e_1_3_4_2_2 e_1_3_4_8_2 e_1_3_4_41_2 e_1_3_4_6_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_45_2 e_1_3_4_20_2 e_1_3_4_43_2 e_1_3_4_26_2 e_1_3_4_49_2 e_1_3_4_24_2 e_1_3_4_47_2 e_1_3_4_28_2 e_1_3_4_52_2 e_1_3_4_50_2 e_1_3_4_12_2 e_1_3_4_33_2 e_1_3_4_58_2 e_1_3_4_54_2 e_1_3_4_10_2 e_1_3_4_31_2 e_1_3_4_16_2 e_1_3_4_37_2 e_1_3_4_14_2 e_1_3_4_35_2 e_1_3_4_56_2 e_1_3_4_18_2 e_1_3_4_39_2 |
| References_xml | – ident: e_1_3_4_2_2 doi: 10.1016/j.cjca.2014.09.011 – ident: e_1_3_4_50_2 doi: 10.1016/j.jacc.2018.02.029 – ident: e_1_3_4_35_2 doi: 10.1056/NEJMoa0808227 – ident: e_1_3_4_17_2 doi: 10.1001/jama.2011.1880 – ident: e_1_3_4_18_2 doi: 10.1161/CIRCULATIONAHA.111.031195 – ident: e_1_3_4_33_2 doi: 10.1093/eurheartj/eht296 – ident: e_1_3_4_56_2 doi: 10.1016/j.ijcard.2017.02.062 – ident: e_1_3_4_3_2 doi: 10.1016/j.amjcard.2015.02.049 – ident: e_1_3_4_52_2 doi: 10.1056/NEJMoa0706482 – ident: e_1_3_4_55_2 doi: 10.1093/eurheartj/ehx419 – ident: e_1_3_4_28_2 doi: 10.1001/jama.2011.290 – ident: e_1_3_4_59_2 doi: 10.3390/jpm8010008 – ident: e_1_3_4_45_2 doi: 10.1016/j.thromres.2011.07.028 – volume: 46 start-page: 594 year: 1994 ident: e_1_3_4_9_2 article-title: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. publication-title: Mol Pharmacol – ident: e_1_3_4_5_2 doi: 10.1001/jama.2009.1232 – ident: e_1_3_4_11_2 doi: 10.1016/S0140-6736(12)60161-5 – ident: e_1_3_4_53_2 doi: 10.1253/circj.CJ-15-0112 – ident: e_1_3_4_16_2 doi: 10.1056/NEJMoa0809171 – ident: e_1_3_4_12_2 doi: 10.1007/s40265-013-0126-z – ident: e_1_3_4_8_2 – ident: e_1_3_4_58_2 doi: 10.1038/nrcardio.2009.154 – ident: e_1_3_4_38_2 doi: 10.1016/j.amjcard.2008.11.048 – ident: e_1_3_4_42_2 doi: 10.1111/j.1538-7836.2011.04483.x – ident: e_1_3_4_32_2 doi: 10.1161/CIR.0b013e3182742cf6 – ident: e_1_3_4_37_2 doi: 10.1016/j.jacc.2007.12.056 – ident: e_1_3_4_40_2 doi: 10.1016/j.jjcc.2010.10.007 – ident: e_1_3_4_6_2 doi: 10.1016/j.jacc.2010.05.013 – ident: e_1_3_4_39_2 doi: 10.1016/j.ahj.2010.06.039 – ident: e_1_3_4_31_2 doi: 10.1161/CIR.0b013e318212bb8b – ident: e_1_3_4_14_2 doi: 10.1111/j.1538-7836.2007.02775.x – ident: e_1_3_4_36_2 doi: 10.1253/circj.72.1165 – ident: e_1_3_4_15_2 doi: 10.1161/CIRCINTERVENTIONS.111.963025 – ident: e_1_3_4_43_2 doi: 10.1136/hrt.2011.227272 – ident: e_1_3_4_49_2 doi: 10.1161/CIR.0000000000000404 – ident: e_1_3_4_44_2 doi: 10.1161/CIRCULATIONAHA.109.885194 – ident: e_1_3_4_21_2 doi: 10.1161/CIRCULATIONAHA.109.851949 – ident: e_1_3_4_27_2 doi: 10.1056/NEJMoa1209979 – ident: e_1_3_4_48_2 doi: 10.1016/j.jcin.2017.07.022 – ident: e_1_3_4_57_2 doi: 10.1016/j.ahj.2014.03.006 – ident: e_1_3_4_4_2 doi: 10.1016/j.jacc.2011.11.068 – ident: e_1_3_4_29_2 doi: 10.1016/j.jacc.2013.07.101 – ident: e_1_3_4_46_2 doi: 10.1001/jama.2010.1543 – ident: e_1_3_4_20_2 doi: 10.1007/s10928-008-9103-7 – ident: e_1_3_4_34_2 doi: 10.1016/S0140-6736(17)32155-4 – ident: e_1_3_4_54_2 doi: 10.1161/CIR.0000000000000133 – ident: e_1_3_4_7_2 doi: 10.1016/S0021-9258(17)40694-6 – ident: e_1_3_4_10_2 – ident: e_1_3_4_23_2 doi: 10.1161/CIRCGENETICS.110.958561 – ident: e_1_3_4_22_2 doi: 10.1016/S0140-6736(10)61274-3 – ident: e_1_3_4_26_2 doi: 10.1001/jama.2010.181 – ident: e_1_3_4_13_2 doi: 10.1124/dmd.109.029132 – ident: e_1_3_4_19_2 doi: 10.1001/jama.2011.1703 – ident: e_1_3_4_30_2 doi: 10.1161/CIR.0b013e31823a5596 – ident: e_1_3_4_25_2 doi: 10.1016/j.jacc.2018.02.036 – ident: e_1_3_4_24_2 doi: 10.1161/CIRCULATIONAHA.111.075242 – ident: e_1_3_4_51_2 doi: 10.1056/NEJMoa0904327 – ident: e_1_3_4_47_2 doi: 10.1161/CIR.0b013e3181ee08ed – ident: e_1_3_4_41_2 doi: 10.1016/j.jacc.2010.12.047 |
| SSID | ssj0063262 |
| Score | 2.6031203 |
| Snippet | Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and... Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and... Common genetic variation in CYP2C19 (*2 and *3 alleles) leads to a loss of functional protein and carriers of these loss-of-function alleles when treated with... |
| SourceID | pubmedcentral crossref wolterskluwer |
| SourceType | Open Access Repository Enrichment Source Index Database Publisher |
| StartPage | e007811 |
| Title | Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study |
| URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=01337495-201904000-00010 https://pubmed.ncbi.nlm.nih.gov/PMC6581205 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1941-7632 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0063262 issn: 1941-7640 databaseCode: KQ8 dateStart: 20080801 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1941-7632 dateEnd: 20241028 omitProxy: true ssIdentifier: ssj0063262 issn: 1941-7640 databaseCode: DIK dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgSAgJTUOAKAzUh71VDvmw41o8obBpGzAhtqHtKYodW8s2JagtQ9pfz52T5qNMqOwlquzYcnKXu3P9u98RspOrWGVTZWgurE8ZBBRUKhVSCd5S45kid4w3X4_i_VN2eMbPOtiYyy5ZKE_f3plXch-pQhvIFbNk_0Oy7aTQAL9BvnAFCcN1LRknmO6UV7Blvp58azio4WbMS5z3o86kmOmmTJeHEI8BArUHepx3hnJmCleBCMzvDeK4vnjt0Uxx4YoEuJP6rLwsFpPjtvO4qo3YzFxNzr29blA176Bk5zdm8G9DIHsgldpAShZQEdcUS57pt0VDqxr2tIfdbaxjNNbJwffE0f_-2D1ymdPQgRyimALbOanlwfyK72oRhW4vEwfpX7NBs0zr2R6SRyHYfizw8eng89Jfw7pd2dn2yR6TnWZ17_-1tkEgswqoffq7QrDD_MrlOvQilpMtstlsNcYfa715Rh6Y8jnZ7unMeFVnXpDTvd2TZJ82FTKoRuI9anWouQkiawVXkVBS2UznLJ5KJbUJpwoC9ozBx8iEMsxKH6sLsJzrKFOayyx6STbKqjSvyDiGW61VWO8gZBFMITKZMysyE1nuGzkiH5aPm-qGPh6rmFyn67z6EeHt6J81jcqa48TgzbaDkRV92FMWF44dHULqIPT5iNCBDNI6rziFLU8kmOQUtRs9mCNWCPzX91zhG_Kk-062ycZi9su8hTh1od45NfsDgXSMPA |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clopidogrel+Pharmacogenetics&rft.jtitle=Circulation.+Cardiovascular+interventions&rft.au=Pereira%2C+Naveen+L.&rft.au=Rihal%2C+Charanjit+S.&rft.au=So%2C+Derek+Y.F.&rft.au=Rosenberg%2C+Yves&rft.date=2019-04-01&rft.issn=1941-7640&rft.eissn=1941-7632&rft.volume=12&rft.issue=4&rft_id=info:doi/10.1161%2FCIRCINTERVENTIONS.119.007811&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_CIRCINTERVENTIONS_119_007811 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-7640&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-7640&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-7640&client=summon |